Figure 6.

Longitudinal viral loads

Chronically HBV-infected FRG mice were given entecavir to suppress viremia, then injected intravenously with either anti-GFP or anti-HBV AAV-SaCas9 vectors as shown and followed for levels of viremia for 4 (anti-GFP early, anti-HBV early) or 9 (anti-GFP late, anti-HBV late) weeks. Mice were infected with a genotype C HBV inoculum 144 days prior to AAV administration, and entecavir administration was halted at 4 weeks after AAV administration to monitor levels of viremia rebound in control or treated mice. (A and B) All mice were monitored weekly during entecavir (days −17 to 28) and AAV (days 0–62) treatment, and viral loads for grouped (A) and individual (B) mice are shown. Error bars indicate SD.